FDA Gets Senate Funding, House Scolding In Fiscal 2015 Appropriation
This article was originally published in The Tan Sheet
An omnibus spending agreement gives FDA about a 1.3% increase from its fiscal 2014 appropriation. But the Office of the Commissioner still stands to lose $20 million if FDA does not finalize draft guidance on evaluation and labeling of abuse-deterrent opioids by June 30, 2015.
You may also be interested in...
FDA expects few people would get the disease in the U.S., but many could receive a vaccine.
Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.
The requirements to join the new real-time review pilot program strongly resemble those of the breakthrough designation, which could come as an unpleasant surprise for some sponsors.